Lisata Therapeutics, Inc. (LSTA)

NASDAQ: LSTA · IEX Real-Time Price · USD
2.900
-0.090 (-3.01%)
At close: Apr 12, 2024, 4:00 PM
2.775
-0.125 (-4.31%)
After-hours: Apr 12, 2024, 5:12 PM EDT
-3.01%
Market Cap 24.09M
Revenue (ttm) n/a
Net Income (ttm) -20.84M
Shares Out 8.31M
EPS (ttm) -2.58
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 23,014
Open 3.100
Previous Close 2.990
Day's Range 2.870 - 3.100
52-Week Range 1.950 - 4.530
Beta 1.07
Analysts Strong Buy
Price Target 15.00 (+417.26%)
Earnings Date May 7, 2024

About LSTA

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ c... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1980
Employees 25
Stock Exchange NASDAQ
Ticker Symbol LSTA
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to one analyst, the rating for LSTA stock is "Strong Buy" and the 12-month stock price forecast is $15.0.

Price Target
$15.0
(417.26% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

BASKING RIDGE, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...

4 days ago - GlobeNewsWire

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

BASKING RIDGE, N.J., April 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...

10 days ago - GlobeNewsWire

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

BASKING RIDGE, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...

23 days ago - GlobeNewsWire

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

Phase 2b ASCEND trial fully enrolled and on track for top-line data in fourth quarter of 2024 Company affirms projection of operational funds into early 2026 Conference call scheduled for today at 4:3...

6 weeks ago - GlobeNewsWire

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

7 weeks ago - GlobeNewsWire

Lisata Therapeutics to Present at BIO CEO & Investor Conference

BASKING RIDGE, N.J., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

7 weeks ago - GlobeNewsWire

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

BASKING RIDGE, NJ, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for t...

3 months ago - GlobeNewsWire

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

LSTA1, the Company's lead investigational product, in combination with standard-of-care therapy, potentiated a complete response in a patient with metastatic gastroesophageal adenocarcinoma LSTA1, the...

3 months ago - GlobeNewsWire

Lisata Therapeutics to Present at NobleCon19 Investor Conference

BASKING RIDGE, N.J., Nov. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

4 months ago - GlobeNewsWire

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., Oct. 26, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

6 months ago - GlobeNewsWire

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standard-of-care versus standard-of-care alone in subjects with advanced solid tumors inc...

6 months ago - GlobeNewsWire

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer

BASKING RIDGE, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

6 months ago - GlobeNewsWire

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

BASKING RIDGE, N.J., Sept. 28, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...

7 months ago - GlobeNewsWire

Lisata Therapeutics Announces First Patient Treated in the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Advanced Solid Tumors

Phase 2a double-blind, placebo-controlled, multi-center, randomized study evaluating LSTA1 in combination with standards of care versus standards of care alone in subjects with advanced solid tumors i...

7 months ago - GlobeNewsWire

Impilo Therapeutics Launches to Enable Nucleic Acid-Based Medicines to Effectively Treat Solid Tumor Cancers

SAN DIEGO , Aug. 15, 2023 /PRNewswire/ -- Impilo Therapeutics, Inc. ("Impilo"), a privately held drug discovery and development company, today announced that it has launched with the mission to enable...

8 months ago - PRNewsWire

Lisata Therapeutics Reports Second Quarter 2023 Financial Results and Provides Business Update

Cash runway projected into first quarter 2026 based on capital conservation measures implemented without impact to clinical development pipeline

8 months ago - GlobeNewsWire

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Malignant Glioma

BASKING RIDGE, N.J., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

8 months ago - GlobeNewsWire

Lisata Therapeutics to Report Second Quarter 2023 Financial Results on Monday, August 14 After Market Trading and to Host Conference Call on Tuesday, August 15 at 8:30 a.m. Eastern Time

BASKING RIDGE, N.J., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

8 months ago - GlobeNewsWire

Lisata Therapeutics Announces Retirement of Dr. Erkki Ruoslahti from Board of Directors

Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company Lasker Prize winning researcher and serial entrepreneur will remain an advisor to the Company

9 months ago - GlobeNewsWire

Lisata Therapeutics to Present at the GCFF Innovation and Healthcare Virtual Conference

BASKING RIDGE, N.J., June 12, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for...

10 months ago - GlobeNewsWire

Lisata Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Update

Conference call scheduled for today at 4:30 p.m. Eastern time BASKING RIDGE, N.

1 year ago - GlobeNewsWire

Lisata Therapeutics to Host First Quarter 2023 Financial Results Conference Call on Tuesday, May 9th, at 4:30 p.m. Eastern Time

BASKING RIDGE, N.J., May 02, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies for ...

1 year ago - GlobeNewsWire

Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program

BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative therapies fo...

1 year ago - GlobeNewsWire

Lisata Therapeutics and WARPNINE Announce First Patient Treated in the iLSTA Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide, in Patients with Locally Advanced Non-Resectable Pancreatic Ductal Adenocarcinoma

The iLSTA Trial is the first study combining LSTA1 with standard-of-care chemotherapy and immunotherapy WARPNINE to provide funding and local trial management BASKING RIDGE, N.J. and SUBIACO, Australi...

1 year ago - GlobeNewsWire

Lisata Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update

Conference call scheduled for today at 4:30 p.m. Eastern time Conference call scheduled for today at 4:30 p.m. Eastern time

1 year ago - GlobeNewsWire